Literature DB >> 23073618

Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis.

Igor A Sobenin1, Vasily P Karagodin, Alexandra Capital A Cyrillic Melnichenko, Yuri V Bobryshev, Alexander N Orekhov.   

Abstract

Recently, it has been shown that increased level of LDL-containing circulating immune complexes (LDL-CIC) possess high diagnostic significance in clinically manifested atherosclerosis, but little is known about its diagnostic and prognostic significance in early atherosclerosis. Two-years prospective study was performed in 98 asymptomatic men aged 40-74. The rate of atherosclerosis progression was estimated by high-resolution B-mode ultrasonography as the increase in intima-media thickness (IMT) of common carotid arteries. The patients with elevated baseline levels of LDL-CIC were characterized by significantly higher levels of total and LDL cholesterol as well as significantly increased mean IMT of common carotid arteries. Among all baseline lipid parameters, only LDL-CIC and LDL cholesterol were contingent with the extent of early carotid atherosclerosis (p = 0.042 and p = 0.049, respectively) and had the highest levels of relative risk and odds ratio. During the follow up, significant IMT increase was registered in 53.1 % (n = 52) patients, IMT significant reduction was observed in 21.4 % (n = 21) patients. The increased levels of LDL-CIC, total serum cholesterol and LDL cholesterol had similar prognostic significance with the respect of atherosclerosis progression. The normal level of LDL-CIC (below than 16.0 μg/ml) was the only lipid parameter that predicted the absence of carotid atherosclerosis progression for two following years at prognostic value of 78.3 %. The results of the study allow assuming that LDL-CIC level may be employed not only as a marker of early atherosclerosis, but also has a sufficient prognostic value for clinical implications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073618     DOI: 10.1007/s10875-012-9819-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  33 in total

Review 1.  Monocyte recruitment and foam cell formation in atherosclerosis.

Authors:  Yuri V Bobryshev
Journal:  Micron       Date:  2005-11-09       Impact factor: 2.251

2.  Antibody against oxidized low-density lipoprotein predicting myocardial infarction.

Authors:  M Puurunen; M Mänttäri; V Manninen; L Tenkanen; G Alfthan; C Ehnholm; O Vaarala; K Aho; T Palosuo
Journal:  Arch Intern Med       Date:  1994-11-28

3.  Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits.

Authors:  G K Hansson; G Bondjers; A Bylock; L Hjalmarsson
Journal:  Exp Mol Pathol       Date:  1980-12       Impact factor: 3.362

4.  Characteristics of low density lipoprotein isolated from circulating immune complexes.

Authors:  V V Tertov; I A Sobenin; A N Orekhov; O Jaakkola; T Solakivi; T Nikkari
Journal:  Atherosclerosis       Date:  1996-05       Impact factor: 5.162

5.  Autoantibodies against low-density lipoprotein and atherogenic potential of blood.

Authors:  A G Kacharava; V V Tertov; A N Orekhov
Journal:  Ann Med       Date:  1993-12       Impact factor: 4.709

6.  Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques.

Authors:  D Parums; M J Mitchinson
Journal:  Atherosclerosis       Date:  1981 Jan-Feb       Impact factor: 5.162

7.  Lipoprotein immune complexes as markers of atherosclerosis.

Authors:  A N Orekhov; O S Kalenich; V V Tertov; I D Novikov
Journal:  Int J Tissue React       Date:  1991

8.  Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells.

Authors:  A N Orekhov; V V Tertov; S A Kudryashov; V N Smirnov
Journal:  Circ Res       Date:  1990-02       Impact factor: 17.367

9.  Circulating IgA-Lp complexes in Watanabe heritable hyperlipidemic and cholesterol fed NZW rabbits.

Authors:  J L Beaumont; P Vivier
Journal:  Atherosclerosis       Date:  1990-06       Impact factor: 5.162

10.  Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation.

Authors:  A N Orekhov; V V Tertov; A E Kabakov; S N Pokrovsky; V N Smirnov
Journal:  Arterioscler Thromb       Date:  1991 Mar-Apr
View more
  6 in total

Review 1.  Thirty-Five-Year History of Desialylated Lipoproteins Discovered by Vladimir Tertov.

Authors:  Victor Glanz; Evgeny E Bezsonov; Vladislav Soldatov; Alexander N Orekhov
Journal:  Biomedicines       Date:  2022-05-19

Review 2.  Opinion: On the Way towards the New Paradigm of Atherosclerosis.

Authors:  Alexander A Mironov; Galina V Beznoussenko
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

Review 3.  Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside.

Authors:  Alexandre Mezentsev; Evgeny Bezsonov; Dmitry Kashirskikh; Mirza S Baig; Ali H Eid; Alexander Orekhov
Journal:  Biomedicines       Date:  2021-05-25

Review 4.  Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value.

Authors:  Igor A Sobenin; Jukka T Salonen; Andrey V Zhelankin; Alexandra A Melnichenko; Jari Kaikkonen; Yuri V Bobryshev; Alexander N Orekhov
Journal:  Biomed Res Int       Date:  2014-06-18       Impact factor: 3.411

5.  Approach to reduction of blood atherogenicity.

Authors:  Alexander N Orekhov; Alexandra A Melnichenko; Igor A Sobenin
Journal:  Oxid Med Cell Longev       Date:  2014-06-29       Impact factor: 6.543

Review 6.  Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.

Authors:  Alexander N Orekhov; Yuri V Bobryshev; Igor A Sobenin; Alexandra A Melnichenko; Dimitry A Chistiakov
Journal:  Int J Mol Sci       Date:  2014-07-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.